| 12/13/2024 | BKCVHY | S&P upgrades Jazz
|
| 12/11/2024 | BKCVHY | Moody’s lifts Jazz Pharmaceuticals
|
| 9/19/2024 | CV | Market Commentary: MicroStrategy convertibles shoot higher on strong day for Bitcoin; Jazz on the rise
|
| 9/6/2024 | CV | Jazz Pharmaceuticals greenshoe ups 3.125% exchangeables to $1 billion
|
| 9/6/2024 | CV | Market Commentary: Varonis Systems convertibles expand on debut; Travere Therapeutics jumps; Jazz lower
|
| 9/6/2024 | CV | Market Commentary: Morning Commentary: Varonis Systems convertible notes upsized, expand on debut
|
| 9/5/2024 | CV | Market Commentary: Varonis convertible notes offering eyed; Jazz climbs higher; Core Scientific jumps
|
| 9/4/2024 | CV | Market Commentary: Jazz Pharmaceuticals exchangeables price, expand on trading debut; Zscaler contracts
|
| 9/4/2024 | CV | Market Commentary: Morning Commentary: Jazz Pharmaceuticals exchangeables price, expand on trading debut
|
| 9/4/2024 | BKCVHY | Fitch rates Jazz notes BB
|
| 9/4/2024 | CV | New Issue: Jazz Pharmaceuticals sells $850 million six-year exchangeable notes at 3.125%, up 40%
|
| 9/3/2024 | CV | Market Commentary: Convertibles primary market reactivates; Jazz Pharmaceuticals on deck; Alibaba active
|
| 9/3/2024 | CV | Market Commentary: Morning Commentary: Convertibles primary reactivates; Jazz Pharmaceuticals on deck
|
| 9/3/2024 | CV | Jazz Pharmaceuticals talks $850 million six-year exchangeables at 3.125%-3.625%, up 37.5%-42.5%
|
| 7/22/2024 | CV | Jazz Pharmaceuticals fixes settlement method for notes due 2026
|
| 6/13/2024 | BKCVHY | S&P assigns BB- to Jazz Financing Lux loan
|
| 3/28/2024 | BKCVHY | Fitch raises Jazz
|
| 1/25/2024 | BKCVHY | Moody’s upgrades Jazz Pharmaceuticals
|
| 7/5/2023 | BKCVHY | S&P moves Jazz outlook to positive
|
| 1/20/2023 | BKCVHY | Moody's views Jazz Pharma positively
|
| 7/8/2022 | CV | Market Commentary: Upstart convertible notes tank on earnings warning; Jazz Pharmaceuticals in focus
|
| 5/13/2022 | BKCVHY | Fitch revises Jazz outlook to positive
|
| 4/11/2022 | BKCVHY | Moody's turns Jazz Pharma view to stable
|
| 8/4/2021 | CV | Market Commentary: Alphatec on tap; Envestnet in focus; Jazz down outright, expands dollar-neutral
|
| 5/5/2021 | BKCVHY | S&P cuts Jazz Pharmaceuticals
|
| 4/23/2021 | BKCVDDEMIGPV | Market Commentary: Triple-hook deals in Friday junk primary; Jazz, Imperial Dade at a premium; goeasy gains
|
| 4/21/2021 | BKCVHY | S&P rates Jazz notes BB-
|
| 4/20/2021 | BKCVDDEMIGPV | Market Commentary: High yield: Morgan Automotive prices; Jazz megadeal on tap; Charter flat; Emergent down again
|
| 4/20/2021 | BKCVHY | Fitch rates Jazz notes BB+
|
| 4/20/2021 | BKCVHY | Moody's assigns Jazz Pharma notes Ba2
|
| 4/9/2021 | BKCVHY | Fitch assigns Jazz Pharmaceuticals BB-
|
| 4/9/2021 | BKCVHY | Moody's gives Jazz Pharma facilities Ba2
|
| 4/9/2021 | BKCVHY | S&P rates Jazz loan BB-
|
| 2/4/2021 | BKCV | S&P puts Jazz Pharmaceuticals on watch
|
| 2/4/2021 | BKCV | Moody’s reviews Jazz for downgrade
|
| 2/3/2021 | CV | Market Commentary: MakeMyTrip, Pebblebrook add-on on tap; Mitek skyrockets on debut; U.S. Steel in focus
|
| 11/4/2020 | CV | Market Commentary: Novocure, Lyft, Jazz Pharmaceuticals jump as ballot counts continue past Election Day
|
| 10/9/2020 | CV | Market Commentary: Fiverr convertibles continue to rise; Sunpower skyrockets; Jazz, ON Semiconductor active
|
| 10/9/2020 | CV | Market Commentary: Morning Commentary: Jazz Pharmaceuticals, ON Semiconductor convertibles active early
|
| 6/17/2020 | CV | Market Commentary: Allegheny Technologies, GlaxoSmithKline exchangeables eyed; Jazz, Palo Alto top par
|
| 6/15/2020 | CV | Market Commentary: Convertibles primary market quiet; Pioneer Natural, Southwest Airlines, Jazz volatile
|
| 6/15/2020 | CV | Market Commentary: Morning Commentary: Convertibles quiet early; Palo Alto, Jazz Pharmaceuticals down
|
| 6/12/2020 | CV | Market Commentary: Zendesk, LivaNova convertibles hit aftermarket, trade up on debut; Coupa tops par
|
| 6/9/2020 | CV | Market Commentary: Coupa, WisdomTree convertibles on deck; Okta, Aptiv eyed; Jazz flat; Glaukos volatile
|
| 6/9/2020 | CV | Market Commentary: Morning Commentary: Okta convertibles eyed; Aptiv on deck; Jazz flat; Glaukos volatile
|
| 6/9/2020 | CV | New Issue: Jazz Pharmaceuticals prices $850 million six-year exchangeables to yield 2%, up 40%
|
| 6/8/2020 | CV | Market Commentary: Jazz to price $850 million exchangeable; Glaukos offers seven-year convertible notes
|
| 6/8/2020 | CV | Market Commentary: Morning Commentary: Jazz to price $850 million exchangeable; Glaukos offers seven-year paper
|
| 6/8/2020 | CV | Jazz Pharmaceuticals offers $850 million six-year exchangeable notes
|
| 6/8/2020 | CV | Jazz Pharmaceuticals offers $850 million six-year exchangeable notes
|
| 10/8/2019 | CV | Market Commentary: Convertibles market weighed by equities downturn; primary quiet; NXP Semiconductors eyed
|
| 1/4/2019 | CV | Market Commentary: Ensco convertible notes eyed as crude oil futures bounce; Medicines sees large seller
|
| 12/21/2018 | CV | Market Commentary: Benefitfocus convertibles hit the market, trade up; Illumina expands; Jazz contracts
|
| 11/7/2018 | CV | Market Commentary: Zillow, Mindbody, Jazz Pharmaceuticals, Twilio, Etsy active; Infinera ‘disaster du jour’
|
| 10/29/2018 | CV | Market Commentary: Red Hat convertibles active on buyout, trade at double par; Jazz up; Weatherford tanks
|
| 10/29/2018 | CV | Market Commentary: Morning Commentary: Red Hat active on buyout, trades at double par; Jazz notes improve
|
| 3/29/2018 | CV | Market Commentary: Chegg upsized, expands on market debut; Tesla rebounds; Jazz Pharmaceuticals active
|
| 1/9/2018 | CV | Market Commentary: Wheeler to price add on to 8.75% preferreds; Insulet in demand; GoPro holders hold on
|
| 9/5/2017 | CV | Market Commentary: Convertible debt investors eye recent deals from II-VI, Jazz; hurricanes pressure insurers
|
| 9/5/2017 | CV | Market Commentary: Morning Commentary: Convertible debt investors eye recent deals from II-VI, Jazz Pharmaceuticals
|
| 9/1/2017 | CV | Market Commentary: Convertibles quiet ahead of long weekend; Palo Alto Networks up in line; Acorda off lows
|
| 9/1/2017 | CV | Jazz Pharmaceuticals greenshoe ups 1.5% exchangeables to $575 million
|
| 8/25/2017 | CV | Market Commentary: II-VI’s new 0.25% five-year notes active, give in a little; Jazz softer; Tesla falters
|
| 8/24/2017 | CV | Market Commentary: Convertibles move sideways in quiet trade; new II-VI surges in first-day trading
|
| 8/22/2017 | CV | Market Commentary: II-VI plans new Rule 144A deal; Jazz edges above issue price; Red Hat busy; Teva assets eyed
|
| 8/22/2017 | CV | Market Commentary: Morning Commentary: Jazz’s recent deal pushes above issue price; Red Hat, Palo Alto active
|
| 8/21/2017 | CV | Market Commentary: Convertibles activity wanes; Herbalife gains on news; Vipshop dips; Illumina tracks stock
|
| 8/18/2017 | CV | Market Commentary: Jazz prices at discount, fades post-pricing; AMAG convertibles hold steady; DyCom sees action
|
| 8/18/2017 | BKCV | Moody’s upgrades Jazz debt
|
| 8/18/2017 | CV | Market Commentary: Morning Commentary: Jazz prices at discount, fades post-pricing; AMAG convertibles hold steady
|
| 8/18/2017 | CV | New Issue: Jazz sells $500 million 1.5% seven-year exchangeables at 97, up 50%
|
| 8/17/2017 | CV | Market Commentary: GAIN comes in line; Hannon trades near par post-pricing; Jazz plans deal; Altbaba notes firm
|
| 8/17/2017 | CV | Jazz Pharmaceuticals offers $500 million exchangeables due 2024; price talk 1.5%, up 50%
|
| 3/21/2017 | CV | Market Commentary: Tesla’s convertibles weaken as stock markets broadly sell off; oil-services names lower
|
| 3/21/2017 | CV | Market Commentary: Morning Commentary: Jazz Pharmaceuticals, Vipshop trading firm to better despite stock markets’ sag
|
| 6/1/2016 | BKCV | Moody’s lowers Jazz to negative
|
| 5/31/2016 | CV | Market Commentary: Health care in focus as sector lifts; Softbank mandatory exchangeable into Alibaba on tap
|
| 5/31/2016 | CV | Market Commentary: Morning Commentary: Health care in focus as sector lifts following Celator acquisition news
|
| 5/12/2016 | CV | Market Commentary: Qihoo convertibles slip back; YY trades; health care mostly lower; Jazz, Horizon down
|
| 5/12/2016 | CV | Market Commentary: Morning Commentary: Qihoo 360 convertibles, shares ease; Horizon Pharma, Jazz bonds down
|
| 4/13/2016 | CV | Market Commentary: Health care convertibles mixed; energy ‘trickles back’; China-related names active on data
|
| 4/7/2016 | CV | Market Commentary: Healthcare flies higher as out-of-favor sector enjoys resurgence; DepoMed, BioMarin improve
|
| 1/11/2016 | CV | Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
|
| 1/11/2016 | CV | Market Commentary: Morning Commentary: Depomed convertibles, shares lower; health care in focus during conference
|
| 7/8/2015 | BKCV | Jazz Pharmaceuticals eyes growth through acquisitions, says CFO
|
| 8/27/2014 | CV | Market Commentary: Aegerion adds on swap with higher shares; Titan Machinery slips on swap on lower shares
|
| 8/20/2014 | CV | Market Commentary: Convertibles see better buyers; Jazz Pharmaceuticals outperforms; Royal Gold holds gains
|
| 8/18/2014 | CV | Market Commentary: Gilead Sciences active, trading below parity; Priceline off a bit; USEC convertibles flat
|
| 8/13/2014 | CV | Jazz Pharmaceuticals greenshoe lifts exchangeable sale to $575 million
|
| 8/8/2014 | CV | New Issue: Jazz Pharmaceuticals sells $500 million exchangeables due 2021 at 1.875%, up 47.5%
|
| 8/7/2014 | BKCV | S&P gives Jazz exchangeables B+
|
